Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial

Abstract Background Breast cancer neoadjuvant therapy may negatively impact the immune system. As a secondary outcome of the docosahexaenoic acid (DHA) for women with breast cancer in the neoadjuvant setting (DHA-WIN trial), we sought to assess the effects of an intervention with DHA on parameters o...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaqueline Munhoz, Marnie Newell, Susan Goruk, Sunita Ghosh, Dhruvesh Patel, Anil Abraham Joy, Gilbert Bigras, Vera Mazurak, Kerry S. Courneya, Denise G. Hemmings, Catherine J. Field
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Breast Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13058-025-02048-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items